http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106913562-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4711b7defc1422cdb7f86d2c95657bf
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-235
filingDate 2015-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5c030959e658bddc8a355d975fa0595
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4caa5021661dcfc2795b779b662d0d0
publicationDate 2017-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-106913562-A
titleOfInvention Application of the squamatic acid in antineoplastic sensitizer is prepared
abstract The invention belongs to cell biology and field of medicaments, it is related to application of the squamatic acid in antineoplastic sensitizer is prepared.Squamatic acid is natural products, the effect with reversing multiple medicine resistance of tumor cells, can be as the reversal agent of tumor multi-medicine drug-resistant;Squamatic acid also has increases the effect of tumor multi-medicine drug-resistant cells against neoplastic drug susceptibility, can be used as chemotherapeutic sensitizer.Present invention also offers the method that the pharmaceutical composition that antineoplastic and squamatic acid are used in combination suppresses tumor multi-medicine drug-resistant cell propagation.Micromolecular compound squamatic acid in the present invention is developed as new antineoplastic or its auxiliary element, and substantially, environmental protection will provide a kind of new approach and means to tumor killing effect to treat and curing tumour.
priorityDate 2015-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP23916
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35034
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00775
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83348
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00764
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35051
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492855
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426072862
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504230
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35050
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35049
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5978
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81071
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2520
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504969
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP70059
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419585571
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP51588
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00761
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19799
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5321482
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ59149
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP24664
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506849
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3385
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO97399
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35048

Total number of triples: 44.